← Back to Clinical Trials
Recruiting NCT05653063

NCT05653063 ARCHERY - Artificial Intelligence Based Radiotherapy Treatment Planning for Cervical, Head and Neck and Prostate Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05653063
Status Recruiting
Phase
Sponsor University College, London
Condition Cancer of Prostate
Study Type OBSERVATIONAL
Enrollment 990 participants
Start Date 2023-12-07
Primary Completion 2025-12-01

Trial Parameters

Condition Cancer of Prostate
Sponsor University College, London
Study Type OBSERVATIONAL
Phase N/A
Enrollment 990
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-12-07
Completion 2025-12-01
Interventions
A web-based artificial intelligence (AI) auto-planning tool

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The aim of this study is to look at whether an Artificial Intelligence (AI) based computer program can automate two components of the radiotherapy treatment pathway to a sufficient quality standard to enable its routine clinical use. The two components include the delineation (outlining) of anatomical areas that are at risk of tumour spread and at risk of radiation damage, and the definition of the position, size and shape of the radiation beams. The AI-based computer programs have been developed to perform tasks that would normally require direct human involvement by oncologists and medical physicists. Proposed advantages include improved treatment accuracy, as well as a reduction in the time (from weeks to minutes) and human resources needed to deliver radiotherapy, which this study will test.

Eligibility Criteria

Inclusion Criteria: 1. Consecutive patients with histologically confirmed head and neck cancers of the oropharynx, larynx, hypopharynx and nasopharynx (Stage I-III) that have given consent for radical radiotherapy. 2. Consecutive histologically confirmed primary cervical cancer patients (Stage IB-IIIB including pelvic node positive) that have given consent for radical radiotherapy. 3. Consecutive histologically confirmed primary prostate cancer patients (T1-4N0M0) that have given consent for radical radiotherapy. 4. Mental capacity to understand and consent to participate in the study. 5. Patients aged ≥18years. Exclusion Criteria: 1. Patients requiring radiotherapy after curative surgery or surgery that is intended to remove as much of the tumour as possible. 2. Patients receiving palliative radiotherapy 3. Patients aged \< 18years.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology